Abstract: The present invention relates to antibodies, including humanized antibodies that bind human Microfibrillar-associated protein 4 (MFAP4). The invention also relates to uses of such antibodies.

Abstract: The present invention relates to antibodies, including humanized antibodies that bind human Microfibrillar-associated protein 4 (MFAP4). The invention also relates to uses of such antibodies.

Abstract: Microfibrillar-associated protein 4 (MFAP4) binding antibodies are provided to prevent or to inhibit the proliferation of vascular smooth muscle cells and neointima formation in blood vessels. Furthermore, there are provided antibodies that effectively inhibit remodelling of vessels and prevent progression of arteriosclerosis as well as restenosis of vessels. The provided antibodies block the interaction between MF AP4 and integrin receptors.

Abstract: Microfibrillar-associated protein 4 (MFAP4) binding antibodies are provided to prevent or to inhibit the proliferation of vascular smooth muscle cells and neointima formation in blood vessels. Furthermore, there are provided antibodies that effectively inhibit remodelling of vessels and prevent progression of arteriosclerosis as well as restenosis of vessels. The provided antibodies block the interaction between MF AP4 and integrin receptors.

Abstract: The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the correspond mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof.

Abstract: The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the corresponding mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof.